Glucocorticoids are used in the treatment of acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL) but many patients develop glucocorticoid resistance on relapse. The ligand-activated glucocorticoid receptor inhibits activity of the AP-1 transcription factor and the purpose of this study was to test the hypothesis that up-regulation or overexpression of AP1-binding activity may be an important mechanism of glucocorticoid resistance in ALL and CLL. In vitro sensitivity of patient blasts to prednisolone was measured using the MTT assay. AP-1 levels were quantified by gel shift analysis and Fos and Jun levels were compared by Western blotting. To test for a relationship between glucocorticoid sensitivity and glucocorticoid-induced changes in AP-1 binding activity, leukaemic blasts were also treated with prednisolone before analysis. Sensitivity of patient blasts to prednisolone varied, with IC 50 values varying over a concentration range from 10 
Introduction
Glucocorticoids form an important part of treatment protocols for many haematological malignancies, particularly acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL). In ALL approximately 20% of patients are resistant to glucocorticoids at time of presentation but in those patients that relapse up to 80% are resistant. 1, 2 The actions of glucocorticoids are mediated through specific intracellular glucocorticoid receptors (GR) found in almost all mammalian cells. The human GR is an acidic phosphoprotein with a molecular weight of 97 kDa. 3 In the absence of ligand the receptor is believed to be localised to the cytoplasmic compartment of the cell 4 bound by chaperone proteins, which include heat shock proteins. 5 Glucocorticoids enter cells by a variety of mechanisms including passive diffusion. 4 Binding of glucocorticoid to the ligand-binding domain of GR results in dissociation of the receptor from chaperone proteins. The receptor then enters the nucleus and binds to specific DNA sequences or glucocorticoid response elements (GRE) associated with the promoters of glucocorticoid responsive genes as a dimer.
Resistance to glucocorticoids may occur at various stages in the action of the GR. Although the p-glycoprotein pump (p-gp) plays a role in glucocorticoid transport 6 the efflux of glucocorticoids by p-gp is not thought to be a significant contributor to glucocorticoid resistance in leukaemic blasts. 7, 8 The multi-drug resistance (mdr) phenotype is found in some patients with adult ALL 7 but not in the majority of patients resistant to glucocorticoids. In CLL patients, p-glycoprotein expression is not related to glucocorticoid resistance. 8 Mutations in GR are rare in relation to glucocorticoid resistance in ALL although there are reports of GR mutations in patients with non-lymphoblastic leukaemia. 9 The evidence that the number of receptor sites in ALL and CLL blasts is an important determinant of glucocorticoid sensitivity is inconclusive: some studies have shown a correlation between receptor number and sensitivity [10] [11] [12] while others have not. [13] [14] [15] Furthermore, reduced affinity of GR for its ligand, defective translocation of GR across the nuclear membrane and binding of the GR to the GRE are also not thought to be of major importance in glucocorticoid resistance in leukaemia. 1 A number of other possible mechanisms of resistance to glucocorticoids may occur downstream of the action of the receptor. The inhibition of poly-ADP-ribose-polymerase (PARP) by benzamide, 3-aminobenzamide and nicotinamide has been shown to enhance GC induced apoptosis. 16, 17 Loss of c-AMP protein kinase may result in a decrease in glucocorticoid sensitivity. 18 Interleukins may also play a role in glucocorticoidmediated apoptosis, especially interleukin-1, gamma interferon, interleukin-2 and -4 19 all of which appear to inhibit apoptosis.
Although the primary mode of action of glucocorticoids is thought to be as a transcriptional regulator via DNA-dependent interaction with the promoters of target genes, it has been suggested that GR can have indirect effects on transcription via protein-protein interactions 20 with other transcription factors. For example, protein-protein interactions between GR and the AP-1 (activator protein 1) transcription factor may reduce the levels of AP-1 available to regulate AP-1 target genes. 21 Since AP-1 is important in cell proliferation, a reduction in AP-1 due to ligand-dependent interactions between GR and AP-1 may lead to apoptosis. 21 If this hypothesis is correct, glucocorticoid resistance may develop as a result of elevated levels of AP-1 or induction of AP-1 in response to glucocorticoid treatment. To test this hypothesis we have investigated AP-1 binding activity in ALL and CLL and the relationship between AP-1 binding activity and glucocorticoid resistance. Since AP-1 is a heterodimer of Fos and Jun proteins it is also important to investigate the levels of these proteins and whether there is any association with glucocorticoid sensitivity.
Materials and methods

Patient samples and cell lines
The CCRF-CEM cells used to develop the assays were obtained from the European Collection of Animal Cell Cultures (ECACC, Porton Down, UK). These cells were originally established from a 4-year-old girl with T cell lymphoblastic leukaemia. 22 They were grown in RPMI medium (Gibco BRL, Paisley, UK) with 10% foetal calf serum (Globepharm, Surrey, UK) and 2 mm glutamine (Gibco BRL). NIH 3T3 cells 23 (ECACC) were used as a positive control for mobility shift experiments and were grown in Dulbecco's modification of Eagle's medium (DMEM; Hyclone Europe) containing 2 mm glutamine (Hyclone, Tyne and Wear, UK) and supplemented with 10% foetal calf serum).
Blasts from bone marrow aspirate samples (ALL) and peripheral blood samples (CLL) were separated from whole blood and marrow using Ficoll and Hypaque (LymphoprepNycomed, Amersham, Buckinghamshire, UK) and used in experiments as detailed below (approved by Newcastle Hospitals and University ethical committee). The blasts from 16 patients with ALL were studied using mobility shift analysis; six were from children at presentation, four from children at relapse and five from adults at presentation ( Table 1 ). The median age at diagnosis was 5.8 years (range 0.7-82.9 years) with a median follow-up of 13 months (range 5.7-70.4 months). The median presenting white cell count was 32.4 × 10 9 /l (range 3.2-565). The lymphocytes from 22 patients with CLL were studied ( Plates were incubated for 4 days at 37°C in humidified air enriched with 5% CO 2 prior to addition of MTT solution. 24 The optical density of solubilised formazan crystals was measured on a multi-well spectrophotometer (Multiskan MCC 340) and used to calculate the cell survival as a percentage of control. IC 50 values were calculated from dose-response curves, as was the per cent survival of cells when exposed to the highest concentration of drug (lower asymptote).
MTT assay
Mobility shift assays
Double-stranded (ds) oligonucleotides with a consensus AP-1 binding site sequence (CGC TTG ATG AGT CAG CCG GAA and TTC CGG CTG ACT CAT CAA GCG) 25 were made on an Applied Biosystems (Warrington, UK) oligonucleotide synthesizer by the University facility for Molecular Biology, University of Newcastle upon Tyne. To prepare nuclear extracts, cells were washed twice in ice-cold PBS and lysed in 10 mm Hepes, pH 7.9, 1.5 mm MgCl 2 , 10 mm KCl, 0.5 mm DTT, 0.2 mm PMSF, 0.1% NP-40 and 0.1 mm EGTA. The nuclei were pelleted and lysed on ice for 20 min by resuspension in nuclear lysis buffer (20 mm Hepes, pH 7.9, 25% glycerol, 1.5 mm MgCl 2 , 0.2 mm EDTA, 0.5 mm DTT and 0.2 mm PMSF) containing 420 mm NaCl, and centrifuged at 100 000 g for 30 min at 4°C. Nuclear extracts were desalted by centrifugation (500 g for 4 min) through Sephadex G50 spin columns in nuclear-lysis buffer. The protein concentration of nuclear extracts was measured using a commercially available protein assay kit (Biorad, Hemel Hempstead, UK). The lactase dehydrogenase (LDH) activity of nuclear extracts was measured to correct for cytoplasmic contamination. Extracts were stored at −20°C prior to analysis.
32 P-labelled ds-oligonucleotide probes were prepared by end-labelling one strand using T4 polynucleotide kinase prior to annealing complementary oligonucleotides for the AP-1 consensus sequence. 25 Nuclear 393 extracts (10 l) were mixed with an equal volume of 20 mm Hepes, pH 7.9, 50 mm KCl, 1 mm MgCl 2 , 0.1 mm EGTA, 0.5 mm DTT, 5 mm AMP, 5 mm spermidine, 5 g/ml yeast tRNA, 75 g/ml poly (dI-dC), 2.5% CHAPS, 1 l of the labelled ds-oligonucleotide probe and incubated at room temperature for 20 min. Six times TBE (0.54 m Tris base, 0.54 m orthoboric acid and 0.3 m EDTA, pH 8.0) was then added and the reaction mixtures immediately loaded on to 5% non-denaturing polyacrylamide gels cooled to 4°C. After electrophoresis at 100 V (cooled to 4°C) the gels were dried and exposed to a phosphorimager screen. Two control wells of nuclear extracts from CCRF-CEM cells were loaded as internal standards on each gel. In the supershift assays, antibodies to Fos and Jun (Calbiochem, Nottingham, UK) were added to the reaction for 30 minutes prior to the addition of label.
Western blotting
Proteins in nuclear extracts were separated by electrophoresis through 13% SDS-polyacrylamide gels. 25 In addition to patient samples, 10 g and 30 g of CCRF-CEM cell lysate were also loaded as a standard on each gel. The gels were blotted on to Hybond C nitrocellulose paper (Amersham Life Sciences, Amersham, UK) and the blots were blocked in TBS/Tween + 5% skimmed milk prior to incubation with c-Fos (1:100) and c-Jun (1:40) antibodies (Calbiochem). The antibodies were affinity purified rabbit polyclonal antibodies and the c-Jun antibody may cross-react with other members of the Jun family. Detection was by enhanced chemiluminescence (ECL) using X-ray film (Kodak, Hemel Hempstead, UK). Quantification of the blots was performed using a densitometer (Bio Image, Millipore, Watford, UK) and related to the two CCRF-CEM protein internal standards, after correcting for protein loading.
Northern blotting
Approximately 10 7 cells were resuspended in 400 l of icecold sterile PBS and lysed by adding 100 l of 1% Nonidet P-40 (BDH, Poole, UK), 0.5% sodium deoxycholate (BDH), 0.1% dextran sulphate (Pharmacia Biosystems, Milton Keynes, UK). The sample was then mixed by inverting 10 times and centrifuged at 6000 g for 30 s at room temperature to pellet the nuclei. The supernatant containing cytoplasmic RNA was transferred to a new microcentrifuge tube containing 500 l of phenol/chloroform (4:1 v/v) and 1% SDS (diluted from a 20% stock solution) and mixed by vortexing. After centrifugation at 10 000 g for 5 min at room temperature, the supernatant was extracted twice more with 500 l of 1:1 phenol/chloroform and once with 500 l of chloroform. RNA was then ethanol-precipitated, recovered by centrifugation (10 000 g at room temperature for 10 min) and size fractionated (20 g of RNA per track) by electrophoresis through a 1.2% formaldehyde-agarose gel. 26 RNA was transferred to nylon membranes (Hybond N; Amersham) by vacuum blotting for 4 h with 1.8 m sodium chloride (BDH), 0.01 m EDTA, 0.1 m sodium phosphate (BDH), pH 7.4 (10 × SSPE) and crosslinked to the membrane for 3-5 min on an ultraviolet transilluminator at room temperature. Northern blots were hybridised with 32 P-labelled cDNA probes for c-Fos (Dr A Sharrocks, Department of Biochemistry, Newcastle upon Tyne), c-Jun (Dr E Black, Beatson Institute, Glasgow, UK) and Leukemia GAPDH (R Offringa, University Hospital, Leiden, The Netherlands).
Results
Glucocorticoid sensitivity in ALL and CLL cells
We have used two measures of glucocorticoid sensitivity based on MTT assay: IC 50 as the point at which cell number was 50% of control untreated cells, and the lower asymptote of the dose-response curves representing the percentage of resistant cells in the sample. In very resistant or sensitive samples where IC 50 values fell outside of the prednisolone concentration range, these were recorded as 10 −4 m or 10 −9 m, respectively. In ALL blasts, prednisolone had a median IC 50 of 3 × 10 −4 m (Figure 1 ). Blasts tended to be either sensitive or resistant to prednisolone in vitro with few intermediate IC 50 values. Conversely, the majority of blast samples from patients with CLL were resistant to prednisolone (median IC 50 
10
−5 m) but with other values spread throughout the concentration range (10 −4 m to 10 −11 m). The lower asymptote values for ALL ranged between 4 and 100% with a median of 40% and for CLL the median was 36.5% (range 4-90%) (Figure 1 ). There were no differences in IC 50 values between those patients with CLL taking prednisolone (n = 11) at the time of obtaining the sample and those not (n = 11) (Mann-Whitney U statistic = 119.0, P = 0.796).
Fos and Jun protein levels in ALL and CLL
Samples from the same patient were repeated more than once and gave the same result and therefore showed that the assay was highly reproducible. CCRF-CEM protein standards (three different concentrations) were used as an internal control in all experiments using patient samples. The relative amounts of Fos and Jun protein in patient blast samples was estimated as arbitrary units relative to CCRF-CEM cell nuclear protein.
Fos protein was clearly detectable in patient blasts but with a ෂ300-fold range within ALL and CLL patient samples (ALL median 0.911, range 0.01-2.21; CLL median = 0.87, range 0.02-5.06) (Figure 2 ). Fos expression was not related to in vitro prednisolone sensitivity (MTT assay) for either ALL (Spearman rank correlation coefficient (r s ) = −0.04, P = 0.9) or CLL samples (r s = 0.12, P = 0.63). There was a similar variation in relative expression of Jun protein in ALL (median 1.15, range 0.02-5.4) and CLL (median 0.75, range 0.01-15.6), and this variation was not related to prednisolone sensitivity in vitro for ALL (r s = 0.1, P = 0.7, n = 13) or CLL blasts (r s = 0.08, P = 0.4, n = 21). There was no significant correlation between the expression of Fos and Jun in ALL (r s = 0.5, P = 0.19, n = 13) or CLL (r s = 0.44, P = 0.09, n = 21).
To ask if Fos protein expression changed in response to drug exposure, blasts were treated for 4 h with prednisolone in vitro. Changes in Fos protein in response to prednisolone were not related to in vitro glucocorticoid sensitivity (ALL P = 0.15, CLL P = 0.17). There was also no relationship in ALL with event-free survival (EFS) (log rank test P = 0.18), WBC at presentation (r s = 0.09, P = 0.79. Spearman) or age at presentation (r s = 0.28, P = 0.37). Changes in c-Jun expression in ALL did not correlate with in vitro prednisolone sensitivity as measured by the MTT assay in both ALL (r s = −0.65, P = 0.08, n = 9) nor in CLL (r s = −0.4, P = 0.18, n = 10). Combining ALL and CLL Jun expression in relation to in vitro prednisolone treat-
Figure 2
Examples of Western blots from protein extracted with patients blasts (CLL patients) with and without glucocorticoid treatment. Fos is shown above and Jun below. These were quantified on a densitometer. The graph below shows protein induction or repression with in vitro prednisolone treatment. ment also did not significantly correlate with in vitro prednisolone sensitivity (r s = −0.43, P = 0.06). There was no relationship between changes in c-Jun expression in ALL and EFS (log rank, P = 0.46), age at presentation (r s = 0.25, P = 0.47) and WBC at presentation (r s = 0, P = 1).
Mobility shift analysis of AP1 levels in ALL and CLL
A mobility shift assay to quantify AP-1 binding was developed and validated using the CCRF-CEM T cell lymphoblastic leukaemia cell line. A band representing specific binding to the AP-1 oligonucleotide was competed out by a 500-fold excess of unlabelled AP-1 oligonucleotide but not by an excess of an unrelated oligonucleotide. The signal intensity of the band was related to the amount of protein present (Figure 3 ). The addition of Fos and Jun antibodies resulted in a second band (supershift); no supershift was observed with glucocorticoid receptor and glutathione S-transferase antibodies used as negative controls (Figure 3 ). AP-1 activity is induced by tumour promoters such as phorbol esters in NIH 3T3 cells 27 and enhanced by the calcium ionophore ionomycin (Sigma) as shown by gel shift experiments. 28 NIH 3T3 cells were therefore used as a positive control and showed induction of AP-1 activity in response to phorbol ester and ionomycin as a Samples from the same patient were repeated more than once and gave the same result and therefore showed that the assay was highly reproducible. A CCRF-CEM protein standard was used as an internal control in all experiments using patient samples.
CCRF-CEM cells and patient samples were incubated for 4 h with prednisolone prior to extraction of nuclear protein.
In time-course experiments, induction of AP-1 was found to be at a maximum after 4 h incubation with prednisolone and in dose-response experiments 2 × 10 −7 m prednisolone maximally induced AP-1. Apoptosis was seen in cells after 24 h (maximally at 48 h) after 4 h exposure to prednisolone with subsequent removal of the drug.
Gel shift analysis demonstrated the presence of specific AP-1 binding activity in nuclear extracts from ALL and CLL blasts ( Figure 5 ). Contrary to the CCRF-CEM cells, two specific AP-1-bands were observed in these extracts: the intensity of these bands was directly proportional to the amount of nuclear protein and both bands were competed out by an excess of unlabelled AP-1 oligonucleotide ( Figure 5 ). All patient samples had two bands and the ratio between them was similar in all samples.
Prednisolone sensitivity in vitro was not related to AP-1 binding activity in either ALL (r s = −0.12, P = 0.67, n = 14 ) or CLL (r s = −0.22, P = 0.36, n = 20) blasts. AP-1 binding activity was measured in five patients with CLL on more than one
Figure 5
Example of a mobility shift assay on patient samples using the AP-1 oligonucleotide. *Treated with in vitro prednisolone.
Leukemia occasion. AP-1 binding was unchanged in two samples and marginally increased with time in the remaining three samples. These patients were not on glucocorticoids at the time of either sample.
The change in relative AP-1 binding activity in response to blasts treated with in vitro prednisolone varied from −1.3 to 1.2 for ALL and −0.2 to 0.9 in CLL ( Figure 6 ). These changes in AP-1 binding activity did not correlate with in vitro measures of glucocorticoid sensitivity using the MTT test in ALL blasts (r s = 0.28 P = 0.44, n = 10) nor in blasts from patients with CLL (r s = 0.17, P = 0.48, n = 15). Changes in AP-1 binding activity in blasts from patients with ALL were not related to event-free survival (log rank, P = 0.28), presenting white blood count (r s = 0.4, P = 0.15) or age at diagnosis (r s = 0.07, P = 0.15).
Discussion
The results of this study demonstrate clearly that glucocorticoid resistance in ALL and CLL was not accompanied by changes in AP-1 binding activity or levels of the Fos and Jun components of AP-1. Although AP-1 regulates the transcription of genes necessary for cell proliferation, 29 the role of AP-1 in apoptosis is ill defined. AP-1 increases in response to apoptotic stimuli and while it is not essential for subsequent apoptosis, [29] [30] [31] AP-1 appears to be more important where apoptotic signalling is dependent on protein synthesis. 32 Levels of c-Jun also increase in response to apoptotic stimuli in a number of cell types, [32] [33] [34] [35] including CCRF-CEM cells, 35 either as a result of increased mRNA levels or increased protein stability. 36, 37 In the present study, changes in c-Jun levels in response to prednisolone were not related to prednisolone sensitivity but there was a trend (just failing to reach statistical significance at the P = 0.05 level) for decreased c-Jun levels with increased prednisolone resistance in vitro. Although the role of glucocorticoids in the regulation of c-Jun is unknown, this may itself be a reflection of glucocorticoid resistance and level of apoptotic stimulus in response to prednisolone.
Previous attempts to elucidate mechanisms of glucocorticoid resistance have focussed on receptor levels, and on genetic defects underlying total resistance, which, although uncommon, is easy to define. 38 Two obvious mechanisms of glucocorticoid resistance relate to either defective ligand or DNA binding by the glucocorticoid receptor. [38] [39] [40] Since chaperone proteins are closely associated with cytosolic glucocorticoid receptors, variation in the expression of these proteins or other elements in the pathways by which activated receptor is translocated to the nucleus are other mechanisms that could account for variation in glucocorticoid sensitivity. Recent studies have shown that high levels of circulating cortisol in squirrel monkeys are associated with elevated expression of the peptidylprolyl isomerase immunophilin FKBP51. 41 This immunophilin is widely expressed in human tissues 42 and associates with the glucocorticoid/Hsp90 complex where it may function to regulate the intracellular availability of glucocorticoid receptors. 41, 43 Thus, variation in levels of the chaperone proteins Hsp90 or immunophilins (FKBP51) could be determinants of glucocorticoid sensitivity in ALL and CLL.
Clearly, the differential expression of cytosolic proteins may regulate the access of ligand to GRs. At the other end of the glucocorticoid control pathway, nuclear proteins may regulate access of ligand-activated-and response-element-associated GR to transcriptional machinery. Recent studies have emphasized that varying levels of co-activators (necessary for interactions of ligand-dependent GR with the pre-initiation transcription complex) and co-repressors will determine the ability of ligand-activated GR regulate transcription. 44, 45 For example, RIP140 interacts with ligand-bound GR and in mammalian cells can repress GR function. 46 Similarly, it has recently been shown that recruitment of the Bcl-2 family member BAG-1 (RAP46) to the nucleus results in a down-regulation of GRmediated transcriptional regulation. 47 BAG-1 is an anti-apoptotic protein and over-expression may cause resistance to apoptosis both by inhibiting caspase-3 activity and inhibiting GR-dependent transactivation. 48 An alternative mechanism of variation in glucocorticoid sensitivity may relate to altered splicing patterns leading to changes in the ratio of the GR␣ and GR␤ isoforms. GR␤ is reported to act as a dominant-negative inhibitor of glucocorticoid action by competitively inhibiting the GR␣ isoform; thus, increased expression of GR␤ relative to GR␣, perhaps as a result of alteration in the relative abundance of particular SR splicing proteins, may account for glucocorticoid resistance. 49, 50 Clearly, there is considerable scope for further studies on immunophilins and GR isoforms as possible mechanisms of glucocorticoid resistance in ALL and CLL. Elucidating the mechanisms involved will bring considerable benefits by facilitating the design of clinical strategies to overcome glucocorticoid resistance.
